1 day+1.45%
1 week+8.53%
Current month+13.82%
1 month+67.06%
3 months+88.17%
6 months+72.41%
1 week 134
Extreme 134
152.5
1 month 87.4
Extreme 87.4
153.5
Current year 37.55
Extreme 37.55
153.5
1 year 37.55
Extreme 37.55
153.5
3 years 37.55
Extreme 37.55
153.5
5 years 37.55
Extreme 37.55
153.5
10 years 37.55
Extreme 37.55
153.5
Manager TitleAgeSince
Chief Tech/Sci/R&D Officer - 12/01/2017
Chief Executive Officer - 12/01/2017
Director of Finance/CFO - 22/09/2019
Director TitleAgeSince
Director/Board Member 52 24/07/2019
Chairman - 12/01/2017
Director/Board Member - 22/10/2025
Change 5-day change 1-year change 3-year change Capi.($)
+1.45%+8.53% - - 594M
-0.56%-8.08%-3.88%+10.58% 46.05B
-2.08%-3.57%+402.72%+533.09% 43.59B
+0.12%-5.27%+39.94%+20.50% 42.35B
-2.62%-5.76%+8.88%+77.44% 38.86B
-1.26%-3.37%+11.87%+40.55% 32.24B
+0.16%-3.65% - - 17.16B
-0.54%-1.72%+22.34%+115.10% 16.28B
-0.03%-3.46%+12.68%+30.90% 14.32B
-1.92%-6.94%+78.12%+36.68% 13.03B
Average -0.73%-3.79%+71.58%+108.10% 26.45B
Weighted average by Cap. -1.08%-4.53%+86.56%+128.49%

Financials

2024 2025
Net sales 803K 25.37K 21.81K 20.58K 18.75K 35.05K 2.43M 35.37K 245K 94.34K 1.23M 95.25K 93.17K 3.91M 50.29M 1.59M 1.37M 1.29M 1.17M 2.2M 152M 2.21M 15.35M 5.91M 77.03M 5.97M 5.83M 245M
Net income -440M -13.91M -11.96M -11.29M -10.28M -19.22M -1.33B -19.39M -134M -51.73M -674M -52.23M -51.09M -2.14B -1.11B -34.95M -30.06M -28.36M -25.84M -48.3M -3.34B -48.74M -338M -130M -1.69B -131M -128M -5.38B
Net Debt - -
Logo Elixiron Immunotherapeutics (Cayman) Limited
Elixiron Immunotherapeutics Cayman Ltd is an investment holding company located in Taiwan, focusing on developing innovative precision immunotherapy drugs for multiple diseases. The Company operates as a new drug research and development enterprise, with products currently in clinical development. Its pipeline is centered on innovative drug development, covering neurodegenerative disorders, immune-related diseases, and oncology. The main clinical-stage candidates are EI-1071 (Enrupatinib) and EI-001 (Indemakitug). EI-1071 (Enrupatinib) is a proprietary small-molecule drug targeting neurodegenerative diseases, with Alzheimer’s disease as its primary indication, currently in Phase II clinical trials. EI-001 (Indemakitug) is an anti-IFNy monoclonal antibody designed for precise immunomodulation in autoimmune diseases.
Employees
-
Date Price Change Volume
10/09/26 NT$140.00 +1.45% 911,318
09/09/26 NT$138.00 -1.08% 1,505,241
08/09/26 NT$139.50 -4.12% 2,296,666
07/09/26 NT$145.50 +4.68% 3,860,087
04/09/26 NT$139.00 +7.75% 2,406,024
  1. Stock Market
  2. Stocks
  3. 7871 Stock
40% Discount: Identify Tomorrow's Best Investments With The Best Subscriber-Only Tools!
d
:
:
SEIZE THE OFFER!